Hodgkin's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Hodgkin's Disease, including details on causes, cancer, lymphoma, stages, symptoms.

Volume 2 (2005), Issue 8 (August)

1. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
   Blood, 106(4): 1473-8. [Abstract] [Full-text]
2. Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype.
   Hum Pathol, 36(7): 747-55. [Abstract] [Full-text]
3. Synchronous development of breast cancer and chest wall fibrosarcoma after previous mantle radiation for Hodgkin's disease.
   Eur Radiol, 15(9): 2018-20. [Abstract] [Full-text]
4. Hodgkin's lymphoma associated with plasma cell neoplasia: cytological features and review of the literature.
   Diagn Cytopathol, 33(3): 181-6. [Abstract] [Full-text]
5. Second primary malignancies after treatment for malignant lymphoma.
   Br J Cancer, 93(4): 418-24. [Abstract] [Full-text]
6. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
   Ann Oncol, 16(9): 1524-9. [Abstract] [Full-text]
7. The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma.
   Leuk Lymphoma, 46(9): 1301-6. [Abstract] [Full-text]
8. Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice.
   Cancer Sci, 96(8): 466-73. [Abstract] [Full-text]
9. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
   J Clin Oncol, 23(24): 5739-45. [Abstract] [Full-text]
10. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.
    Blood, 106(5): 1801-7. [Abstract] [Full-text]
11. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
    Blood, 106(5): 1839-42. [Abstract] [Full-text]
12. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.
    Leukemia, 19(9): 1648-55. [Abstract] [Full-text]
13. Activation induced cytidine deaminase expression in lymphocyte predominant Hodgkin lymphoma.
    J Clin Pathol, 58(9): 1002-4. [Abstract] [Full-text]
14. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Biol Blood Marrow Transplant, 11(9): 688-97. [Abstract] [Full-text]

© 2004-2008 Hodgkin's Disease Research Today. All Rights Reserved.